

Index

A

Acar, M., 13
Acetylcholine (Ach), 67
Acute myeloid leukemia (AML), 21, 122
Adipoq-Cre/ER mice, 10
Adipoq-Cre⁺LepR⁺ progenitors, 10
Aged myofiber (agMF), 155
Alcian blue (pH 2.5), 174, 178
Alcolea, M.P., 188–202
Al-Hajj, M., 211
 α -Smooth muscle actin (α -SMA), 216
Amnion, 238
Amniotic membrane, 239, 240
Andreopoulou, E., 82–104
Angiogenesis, 9, 25, 127
Angiopoietin-1 (ANG1), 21
Anosmin-1, 92
Aorta-gonad-mesonephros (AGM), 34
Arampatzis, A., 82
Arteriolar and sinusoidal niches, 12, 13
Astroglial morphology, 97
ATP binding cassette (ABC), 131

B

Barrett's oesophagus (BE), 190, 191
Basal membrane (BM), 144
Basic fibroblast growth factor (bFGF), 132
Battista, S., 255
Betacellulin, 91
Bhutia, S.K., 208, 209, 211–219, 221, 222, 224–226
Birbrair, A., 2
Blaser, B.W., 46
Blood-brain barrier (BBB), 120

Blood vessels (BVs), 88
BMP/RA-inducible neural-specific proteins (BRINP), 99
Bone marrow (BM)
 candidate niche cell, 10, 11
 niche cells, 9
 vasculature, 7, 9
Bone marrow derived cells (BMDCs), 128
Bone morphogenetic proteins (BMPs), 82, 93, 131
Bone-resorbing osteoclasts, 21
Bowman, T.V., 34–36, 38–44, 46–48
Brain-derived neurotrophic factor (BDNF), 150
Brain lipid binding protein (BLBP), 58
Bucala, R., 181
Bumetanide, 67
Bystander effect, 197

C

Cadherin 11, 132
Calcitonin receptor (Calcr), 150
Calvi, L.M., 11
Cancer associated fibroblasts (CAFs), 200, 216
Cancer stem cells (CSCs), 100, 122
Carbonic anhydrase IX (CAIX), 129
Cardiomyocytes, 255
Carroll, K.J., 38
 α -Catulin-GFP reporter, 13
Caudal hematopoietic tissue (CHT), 34
Caudal vein (CV), 44
CD44/ligand/RTK signaling, 24
CD44-positive fibroblasts, 177, 180
Cells of origin (COIs), 124, 125
Cellular FLICE inhibitory protein (cFLIP), 101

- Cellular therapy, 236
 Central canal (CC)
 developmental origin, 56
 GABA, 65
 homogeneous epithelial-like cells, 55
 membrane properties, 62, 63
 natural microenvironment, 56
 origin of cells, 56, 57
 stem cell niche, 64, 66–68
 Central nervous system (CNS), 43
 Cerebrospinal fluid contacting neurons (CSFcNs), 57
 Chakkalakal, J.V., 143
 Choline acetyltransferase (ChAT), 95
 Cholinergic neurotransmission, 95
 Choroid plexus (CP), 91
 Chowdhury, F., 252
 Chronic lymphocytic leukemia (CLL), 24
 Ciliary neurotrophic factor (CNTF), 96
 c-kit⁺GFP⁺ HSC, 13
 Clements, W.K., 42
 Clonal evolution model, 209
 Clonal expansion, 82
 Common lymphoid progenitors (CLP), 14
 Conducting polymers (CPs), 253
 Core-binding factor (CBF), 46
 Cozzolino, A.M., 252
 Cre recombinase (CreER), 63
 CRIPR technology, 202
 Curry, J.M., 222
 CXCL12-abundant reticular (CAR) cells, 21, 27
 C-X-C motif chemokine 12 (CXCL12), 21
 CXCR4–CXCL12 interactions, 23
 Cxcl88 signaling, 42
 Cystic fibrosis (CF), 256
 Cytokine receptor family b17 (crfb 17), 41
- D**
 Damaged myofiber (dMF), 146
 Damm, E.W., 42
 Darwinian-like clonal evolution, 210
 3D bioprinting, 248
 Decellularization process, 237
 Dentate gyrus (DG), 55
 DeWard, A.D., 195
 Diethylnitrosamine (DEN), 198
 Dinulovic, I., 141
 3D in vitro culture method, 194
 1,1'-Dioctadecyl-3,3,3',3'-
 Tetramethylindocarbocyanine
 Perchlorate (DiI), 63
 Dorsal aorta (DA), 34
- Drosophila melanogaster*, 85
 Duchenne muscular dystrophy (DMD), 153
 Dvorak, H.F., 199
 Dysferlinopathy, 159
 Dystrophic fiber (dyMF), 158
- E**
 Elastomeric polymers, 255
 Embigin, 9
 Embryonic stem cells (ESCs), 82
 Endodermal cell marker, 175
 Endosteal niches, 13
 Endothelial cells (ECs), 102
 Endothelial nitric oxide synthase (eNOS), 40, 129
 Endothelial-to-hematopoietic transition (EHT), 34
 Energy metabolism, 222
 Ependyma, 69, 71
 Ependymomas, 104
 Epidermal growth factor (EGF), 147
 Epithelial to mesenchymal transition (EMT), 44, 208
 Extensor digitorum longus (EDL), 143
 Extracellular matrix (ECM), 213, 246
 BM, 144
 collagen VI, 147
 fibrillar and non-fibrillar collagens, 144
 FN, 147
 integrins, 147
 proteoglycans, 144
 RL and BL, 144
 tyrosine kinases, 147
 Extracellular signal-regulated kinase (ERK), 101
- F**
 Fatty acid β -oxidation (FAO), 26
 Favaron, P.O., 236
 Fibro/adipogenic progenitors (FAPs), 151
 Fibroblast growth factors (FGFs), 36, 147
 Fibroblast reticular cells (FRCs), 44
 Fibronectin (FN), 147
 Figtree, G., 246–257
 Fractones, 92, 100
 Frizzled-1 (FZD1), 96
 Furrer, R., 141
- G**
 Gamma-amino butyric acid (GABA), 64, 95
 Gastric reflux, 190, 201

- GATA3 transcription factor (GATA3-GFP), 59
 G-CSF-induced mobilization, 11
 Gentile, C., 246–257
 Geroconversion, 156
 Glial fibrillary acidic protein (GFAP), 175
 Glioblastoma (GBM)
 aberrant stem and precursor cells, 126, 127
 cell surface marker expression, 123, 124
 cellular plasticity, 133, 134
 chemo- and radiation therapy, 133
 classification and histopathology, 120
 clonogenic assays, 122
 COIs, 124, 125
 CSCs, 122
 ECM and paracrine factors, 132
 GSCs, 121, 123
 hematopoietic stem cells, 122
 hypoxic niche, 129–131
 microenvironmental components, 134
 perivascular niche, 127–129
 teratomas, 122
 treatment strategies, 120, 121
 tumor progression, 122
 Glioblastoma stem cells (GSCs), 120
 Glioma/glioblastoma (GBM)
 CSC-ECM interactions, 101, 102
 CSCs-vasculature interactions, 102, 103
 diffusible factors, 103
 hypoxia, 104
 GLOBOCAN database, 207
 Glutamate, 98
 Glycosaminoglycan, 174
 Grainger, S., 47
 Granulocyte colony stimulating factor
 (G-Csf), 41, 47
- H**
 Haemolymph, 89
 Handschin, C., 141–161
 He, Q., 41
 Hematopoiesis, 13, 46
 Hematopoietic stem and progenitor cells
 (HSPC), 12
 Hematopoietic stem cell (HSC), 129
 CHT engraftment, 46, 47
 CXCL12, 8, 14
 engraftment, 43, 44, 46
 G α S signaling, 14
 multipotent cells, 5
 murine system, 43
 niche signals, 5, 42, 43
 and PNS neurons, 43
 proliferation, 11
 spatial locations, 11
 structure, 8
 Heparin sulfate proteoglycans (HSPs), 126
 Hepatocyte growth factor (HGF), 146, 147
 Hierarchical model, 209
 HIF response elements (HRE), 130
 Hoechst exclusion assay, 194
 Holmberg, J., 93
 Homeostasis, 2
 Horner, P.H., 58
 Human adult maculae flavae
 arytenoid cartilage, 173
 bone marrow-derived cells, 181
 CD34, CD45 and collagen type I, 181
 cellular mechanotransduction, 182–184
 circulating fibrocytes, 181
 cobblestone-like squamous cells, 176
 cutting-edge methods, 184
 extracellular matrices, 172
 fibroblast-like spindle cells, 176
 glycoproteins and glycosaminoglycan and
 fibrillar proteins, 174
 human vocal fold mucosa, 172
 hyaluronan, 178, 179
 intermediate filaments, 175
 lamina propria, 172
 microenvironment, 178, 184
 newborns, 182
 niche, 172
 side population cells, 182
 telomerase, 175
 thyroid cartilage, 173
 tissue stem cells/progenitor
 cells, 172, 177
 transition cells, 177
 translational medicine, 184
 transmission electron micrograph, 178
 transverse section, 173
 vocal fold stellate cells, 176
 Human oesophagus, 189, 193
 advantages, 192
 mouse models, 193
 suprabasal layers, 193
 Human Papilloma Virus (HPV), 212
 Hyaluronan, 178, 179
 Hyaluronan-mediated regulation, 24
 Hyaluronic acid (HA), 27, 225, 253
 Hydrogels, 253
 Hypothalamic-pituitary-adrenal (HPA), 43
 Hypothalamus, 99, 100
 Hypoxia, 25, 219
 Hypoxia-inducible factor 1 α (HIF-1 α), 25
 Hypoxia-inducible factors (HIFs), 98, 120,
 130, 219

I

- IGF binding proteins (IGFBPs), 148
- Immunohistochemical study, 214
- Immunosuppression, 27
- Induced pluripotent stem cells (iPSCs), 129
- Inflammatory signaling, 40–42
- Instability-induced patterning, 250
- Insulin-like growth factors (IGFs), 147
- Int/Wingless (Wnt), 93
- Integrin heterodimers, 24
- INTEGRIN* $\beta 3$ knockdown, 25
- Integrins, 147
- Interkinetic nuclear migration, 85
- Interleukin-1 β (IL-1 β), 21
- Interleukin-6 (IL-6), 103
- Interleukin-8 (IL-8), 103, 120
- Intrinsic vs. extrinsic regulation
 - ARHGAP11B, 82
 - blastocyst microenvironment, 83
 - ECM, 83
 - human glial progenitors, 83
 - in vitro* and *in vivo* nervous system, 83
 - neuroectodermal/neuroepithelial specification, 82
 - neurogenesis, 83
 - neuroglial system, 82
 - NSCs, 82
 - SoxB gene family, 82
 - stages, 83
 - symmetric and asymmetric divisions, 82
- Itkin, T., 12

J

- Junctional adhesion molecule A (JAM-A), 103

K

- Kazanis, I., 82
- Kempermann, G., 58
- Kim, J.D., 250
- Kobayashi, I., 36
- Konopleva, M., 20–26, 28
- Kruppel-like transcription factor 9 (KLF9), 101
- Kuang, S., 144
- Kusumbe, A.P., 13
- Kwan, W., 43

L

- Leblond, C.P., 194, 195
- Lehtinen, M.K., 86
- Leptin receptor-positive (LepR⁺), 12, 21

- Leukemia stem cell (LSC)
 - BM microenvironment, 20, 27
 - chemoresistant, 20
 - microenvironment, 20
 - therapeutic resistance, 20
- Limb-girdle muscular dystrophy (LGMD), 153
- Lim, S.E., 43
- Lineage tracing, 195, 197, 201
- Lipopolysaccharide (LPS), 41
- Lipoprotein receptor-related protein 2 (LRP2), 93
- Lucas, D., 5–14
- Lymperi, S., 11

M

- Macrophages, 45
- Marichal, N., 55, 57, 60–68, 70, 71
- Matrix metalloproteinases (MMPs), 44, 146, 224
- Mawad, D., 246–257
- McMurray, R.J., 250
- Mechanotransduction, 182–184
- Medulloblastoma, 104
- Megakaryocytes (Mk), 8
- Mesenchymal stem cells (MSCs), 20, 27, 246
- Mesoangioblasts (MABs), 143
- Metabotropic glutamate receptor 5 (mGluR5), 98
- Microenvironment, 2
 - BM niche, 24, 25
 - BM vasculature, 25
 - components, 20–22
 - LSC niche modulation, 22
 - metabolism, 26
- microRNA processing, 22
- Miglino, M.A., 236
- Miniaturized models, 249
- Mintz, A., 120–134
- Miyamoto, K., 11
- Monocyte chemoattractant protein-1 (MCP-1), 151
- Monteiro, R., 39
- Mouse embryonic stem cells (mESCs), 250
- Multidrug resistance 1 (MDR1), 131
- Murayama, E., 43, 44
- Muscle-derived stem cells (MDSCs), 143
- Myelodysplastic syndrome (MDS), 22, 39
- Myeloid-derived suppressor cells (MDSCs), 201
- Myelopoiesis, 41
- Myeloproliferation, 22
- Myeloproliferative neoplasia (MPN), 21
- Myofibroblasts, 217
- Myosin light chain kinase (MLCK), 102

N

Naik, P.P., 208, 209, 211–219, 221, 222, 224–226

Nanofiber scaffolds, 253

Nascent polypeptide-associated complex alpha subunit (NACA), 44

Natalizumab, 24

Natural and synthetic scaffolds, 248

Nerve growth factor (NGF), 150

Neural crest (NC), 42, 43

Neural stem cells (NSCs), 57, 58, 253

- adherens junctions, 86
- ageing, degeneration and cancer stem cell hypothesis, 100
- basal process, 85
- bipolar morphology, 86
- blood vessels, systemic cues and tissue mechanics, 88–90
- cellular and extracellular elements, 83
- centrosome amplification, 82
- ECM components, 83
- evolution, 87, 88
- factors, 86
- integrins, 86
- interkinetic nuclear migration, 85, 86
- mammalian neurogenesis, 85
- N-cadherin and β -catenin, 86
- NEP, 85
- RGCs, 87

Neuroepithelial (NEP), 85

Neurogenic niche, 90

Neurohormones, 99

Neuromuscular junction (NMJ), 150

Neuropilin-2 (NRP2), 104

Neurospheres, 63, 83

Neutrophils, 8

Nguyen, P.D., 38

Niche cells, 21

- BM HSC niches, 6
- bone-lining cells, 20
- cell expansion/ablation, 6
- HSCs and hijack BM, 20
- HSC-supportive factors, 6
- interaction imaging, 7
- osteoblastic (bone-forming) cells, 6
- subpopulations, 20

Nicotine-derived compounds, 198

Nik, S., 34–36, 38–44, 46–48

Nilotinib, 24

Nitric oxide (NO), 40

Norepinephrine, 99

Notch Delta1-dependent signalling, 201

Notch signaling, 36, 197

Nowell, P.C., 210

Nuclear factor-kappa beta activation, 24

O

Oesophageal adenocarcinoma

- clinical implications, 192
- factors, 192

Oesophageal cancer (OEC), 190

- AC, 191
- SCCs, 191

Oesophageal cell behaviour

- DEN, 198
- dysplasia, 199
- notch inhibiting mutations, 197

Oesophageal epithelium, 188

Oesophageal squamous cell carcinoma

- EAC, 191
- genetic alterations, 191

Oesophageal stem cell

- OEC, 191
- piping function, 188
- rodent models, 194
- stomach digestive secretions, 190

Onco-genotype, 209

Oral cancer

- anticancer approaches, 208
- autophagy, 221
- Axl signaling, 216
- CAFs, 217
- CD44+ cells, 212
- CD68 and CD163, 216
- clonal evolution model, 209
- CSC model, 210
- ECM, 213, 214
- fibroblasts shape, 216
- HNSCC, 212
- hypoxia, 219, 220
- intratumoral heterogeneity, 211
- microenvironmental stimuli, 219
- MMPs, 224
- neutrophils, 216
- OXPHOS, 222
- PD-L1 expression, 215
- secretome profiles, 217
- STAT-3 signaling, 224
- TAEs, 218
- therapeutic relevance, 209

Oral squamous cell carcinoma (OSCC), 207

Organogenesis, 2

Organs-on-a-chip, 248

Orosphere culture system, 213

Osteoblasts, 20

Osteoclasts, 11, 20
 Osteocytes, 11
 Osteolineage cells (OLC), 8
 Osteoprogenitors, 22
 Oxygen dependent degradation domain
 (ODD), 130

P

Panda, P.K., 208, 209, 211–219, 221, 222,
 224–226
 Pathogen-associated molecular pattern
 (PAMPs), 41
 Patsoni, M., 82
 Periarteriolar niches, 21
 Peripheral nervous system (PNS), 42
 Perivascular
 BM arterioles, 13
 bone marrow, 7
 CXCL12, 8
 macrophages, 8
 niches, 12
 stromal cells, 10
 Peroxisome proliferator-activated receptor γ
 coactivator 1 α (PGC-1 α), 149
 Phosphoinositide 3-kinase (PI3-K), 22, 101
 Physico-chemical approaches
 cardiomyocytes, 255
 CPs, 253
 fabrication tools, 250
 growth factors, 253
 hESCs, 249, 250
 human iPSCs, 254
 hydrogels, 253
 mESCs, 250
 nanofiber scaffolds, 253
 nanofibrous substrates, 250
 polymeric biomaterials, 253
 polypyrrole, 254
 RLSCs, 252
 PI3k-Akt pathway, 224
 Pillay, L.M., 38
 Piping function, 188
 Platelet-derived growth factor (PDGF), 42
 Platelet-derived growth factor BB
 (PDGF-BB), 149
 Polyacrylamide (PA) gels, 252
 Posterior lateral mesoderm (PLM), 34, 35
 Preosteoblast-rich niche, 21
 Prince, M., 212
 Progenitor cells, 58, 60, 61, 64
 Proinflammatory cytokines, 24
 Prosurvival signaling pathways, 23
 Protein kinase A (PKA), 42

Purinergic signaling, 67
 P2X7 receptors, 68, 70

Q

Quan, H., 215
 Quantitative clonal data, 197
 Quantitative methods, 195
 Quiescent niche, 145
 Quintana, E., 211

R

Radial glial cells (RGCs), 57, 85
 RANKL-induced mobilization, 11
 Reactive oxygen species (ROS), 12, 25
 Reali, C., 55, 57, 60–68, 70, 71
 Regenerative medicine, 236
 Resident liver stem cells (RLSCs), 252
 Reticular lamina (RL), 144
 Retinoic acid (RA), 38
 Reverse Warburg effect, 222
 Rho-associated kinase (ROCK), 102
 Rocheteau, P., 143
 Rostral migratory stream (RMS), 90
 Russo1, R.E., 55, 57, 60–68, 70, 71

S

Sacrospenia, 154, 159
 Sai, K.K.S., 120
 Satellite cells (SCs)
 aging, 154, 156
 angiogenic and neurotrophic factors, 160
 biophysical properties, 153
 blood vessels, oxygen, (peri)endothelial
 cells and secreted systemic factors,
 150
 cytokines, 160
 3D biomimetics, 160
 ECM, 141, 144–147
 FAPs, 151
 fibroblasts, 150
 heterogeneity, 143, 144
 immune cells, 151, 152
 motor neurons, 150
 muscle fiber, 148, 149
 muscular dystrophies, 157, 159
 myogenic capacity, 152, 153
 novel imaging and cell tracking
 techniques, 161
 pathological contexts, 153, 154
 polyethylene glycol hydrogels, 160
 sacrospenia, 159

- serum-free quiescence medium and artificial muscle fibers, 161
 - skeletal muscle regeneration and muscle stem cells, 142, 143
 - stem cell population, 160
 - Sato, K., 172–184
 - Sattiraju, A., 120
 - Scaffold free-technologies, 248
 - Schwachman–Bodian–Diamond syndrome, 22
 - Schwank, G., 256
 - Schwann cells, 8
 - Seeding cardiomyocytes, 255
 - Self-assembly of block copolymers, 250
 - Semaphorin 3F (SEMA3F), 104
 - Sequencing studies, 192
 - Serotonergic axons, 95
 - Signal regulatory protein α (SIRP α), 216
 - Signal transducer and activator of transcription 3 (STAT3), 23
 - S-Nitroso-*N*-Acetyl-D,L-Penicillamine (SNAP), 40
 - Somite-derived niche signals, 35, 36, 38
 - Sonic hedgehog (Shh), 93
 - Spinal cord injury (SCI), 68
 - Spinal cord stem cells
 - CreER transgenic mouse, 56
 - ependymal cells, 57
 - hippocampus, 55
 - niche, 63, 64
 - pMN progenitors, 56
 - postnatal spinal cord, 56
 - Stachura, D.L., 47
 - Stage specific embryonic antigen-1 (SSEA-1), 124
 - Stem cell factor (SCF), 46, 47
 - Stem cells (SC)
 - AML, 26
 - applications, 246
 - DNA damage, 24
 - ECM, 237
 - 3D bioprinting, 248
 - 3D cultures, 246
 - elements, 236
 - endosteal surface, 22
 - engineering, 247
 - extracellular matrix, 247
 - fetal membrane tissues, 236
 - functions, 236
 - human and veterinary regenerative medicine, 237
 - hypoxic, 25
 - membrane-bound factors, 21
 - microchannels, 249
 - microfabricated structures, 248
 - morpho-physiological and biochemical characteristics, 236
 - MSCs, 246
 - multipotent, 236
 - organs-on-a-chip, 248
 - self-renewal and retention, 21, 28
 - self-renewal capacity, 236
 - tissue bioengineering, 237
 - Stomach digestive secretions, 190
 - Stromal-derived factor 1 (SDF-1), 91, 102, 148
 - Sub-ependymal zone (SEZ)
 - B1 cells, 90
 - cell-ECM interactions, 92
 - diffusible factors, 93, 94
 - ependyma, choroid plexus and cerebrospinal fluid, 91
 - neurotransmitters and neuromodulators, 94, 95
 - type C cells, 90
 - vasculature, 91, 92
 - Subgranular zone (SGZ)
 - cell-cell and cell-ECM contact, 96
 - diffusible factors, 96, 98
 - metabolic regulation, 98
 - neurotransmission, neuropeptides-neurohormones, 99
 - stem cell niche, 96
 - Sub-ventricular zone (SVZ), 55, 57, 87
 - Surface topography, 252
 - Synthetic biology, 256
 - Systemic steroid hormone, 89
- T**
- Tabé, Y., 20–26, 28
 - Temozolomide (TMZ), 120
 - Tenascin-C, 101
 - Tgf β receptor 2 (Tgf β R2), 39
 - The Cancer Genome Atlas (TCGA), 120
 - Toll-like receptor (TLR) agonists, 41
 - Trachemys scripta elegans*, 71
 - Transforming growth factor beta (TGF- β), 21, 103, 148
 - Travnickova, J., 44
 - T-regulatory (Treg) cells, 21, 215
 - Trujillo-Cenóz, O., 55, 57, 60–68, 70, 71
 - Tsou, Y.H., 252
 - Tumor angiogenesis, 218
 - Tumor associated macrophages (TAMs), 127, 213
 - Tumor heterogeneity model, 210
 - Tumor microenvironment (TME), 208
 - Tumor necrosis factor receptor 1 (TNF-R1), 101

Tumor necrosis factors (TNFs), 41
 Tumor associated fibroblasts (TAFs), 200

V

Van der Kooy, D., 82
 Vascular cell adhesion molecule 1 (VCAM-1),
 24, 27
 Vascular co-option, 128
 Vascular endothelial growth factor (VEGF),
 25, 38, 102, 149
 Vascular endothelial growth factor A
 (VEGF-A), 120
 Vascular mimicry, 129
 Vasculature, 7, 9
 Vasculogenesis, 127
 VCAM-1/VLA-4 interaction, 24
 Ventricular-SVZ, 90
 Ventricular zone (VZ), 85
 Villa-Diaz, L.G., 249
 Vocal fold stellate cells, 176
 von Hippel-Lindau tumor suppressor
 (pVHL), 130

W

Walkley, C.R., 22
 Wang, L., 40
 Warburg effect, 222
 Weinreb, J.T., 34–36, 38–44, 46–48
 Weiss, S., 63

Wholemount staining technique, 197
 Wingless/INT (WNT) signaling, 47, 212

Y

Yang, Q., 39
 Yolk sac, 237, 238

Z

Zebrafish
 blood lineages, 34
choker mutants, 38
 CRISPR/Cas9 genome editing, 34
 embryo, 36, 37
 endothelial niche, 38
 fluorescent proteins, 34
 genetic and chemical screens, 34
 hematopoiesis, 34, 41
 HSC development, 35, 36, 38
 microenvironmental requirements, 35
 model system, 34
 mutants, 40
 patterning and organogenesis, 34
 regenerative properties, 71
 temporal mechanism, 37
 vascular forces, 38–40
 Zhang, J., 254
 Zhang, R., 11
 Zhang, Y., 46